The FGF/FGFR axis as a therapeutic target in breast cancer.
作者： Nicholas J Brady , Pavlina Chuntova , Lindsey K Bade , Kathryn L Schwertfeger
DOI: 10.1586/17446651.2013.811910
关键词:
摘要: Fibroblast growth factor receptor (FGFR) signaling is a vital component of both embryonic and postnatal mammary gland development, which has prompted researchers to investigate its relevance breast cancer potential as therapeutic target. Deregulated FGFR during occurs through various mechanisms, including amplification the genes, aberrant ligand expression, mutations translocations. Recent experimental outcomes involving animal models human cell lines have led initiation multiple early clinical trials investigating safety efficacy small molecule inhibitors. In this article we review most recent discoveries need for further investigation mechanisms FGF/FGFR emerged an oncogenic driver.
expert-reviews.com参考文章(94)
Tomoko Kamiakito, Masashi Fukayama, Nobuo Hanai, Motoo Yamasaki, Morio Koike, Akira Tanaka, Yutaka Kobayashi, Hiroki Yoshida, Akiko Furuya, Ken Kuriki, High Frequency of Fibroblast Growth Factor (FGF) 8 Expression in Clinical Prostate Cancers and Breast Tissues, Immunohistochemically Demonstrated by a Newly Established Neutralizing Monoclonal Antibody against FGF 8 Cancer Research. ,vol. 58, pp. 2053- 2056 ,(1998)
Stacey L Tannheimer, Alnawaz Rehemtulla, Stephen P Ethier, Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE Breast Cancer Research. ,vol. 2, pp. 311- 320 ,(2000) , 10.1186/BCR73
Eve Rodler, Larissa Korde, Julie Gralow, Current treatment options in triple negative breast cancer Breast Disease. ,vol. 32, pp. 99- 122 ,(2011) , 10.3233/BD-2010-0304
Anne Letessier, Fabrice Sircoulomb, Christophe Ginestier, Nathalie Cervera, Florence Monville, Véronique Gelsi-Boyer, Benjamin Esterni, Jeannine Geneix, Pascal Finetti, Christophe Zemmour, Patrice Viens, Emmanuelle Charafe-Jauffret, Jocelyne Jacquemier, Daniel Birnbaum, Max Chaffanet, Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers BMC Cancer. ,vol. 6, pp. 245- 245 ,(2006) , 10.1186/1471-2407-6-245
Astrid Vogel, Juan-Carlos Izpisúa-Belmonte, Concepción Rodriguez, Involvement of FGF-8 in initiation, outgrowth and patterning of the vertebrate limb Development. ,vol. 122, pp. 1737- 1750 ,(1996)
Maria J Garcia, Jessica Pole, Suet-Feung Chin, Andrew Teschendorff, Ali Naderi, Hilal Ozdag, Maria Vias, Tanja Kranjac, Tatiana Subkhankulova, Claire Paish, Ian Ellis, James D Brenton, Paul AW Edwards, Carlos Caldas, None, A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Oncogene. ,vol. 24, pp. 5235- 5245 ,(2005) , 10.1038/SJ.ONC.1208741
Marco Rusnati, Maura Camozzi, Emanuela Moroni, Barbara Bottazzi, Giuseppe Peri, Stefano Indraccolo, Alberto Amadori, Alberto Mantovani, Marco Presta, Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood. ,vol. 104, pp. 92- 99 ,(2004) , 10.1182/BLOOD-2003-10-3433
Lesley-Ann Martin, Fabrice André, Mario Campone, Thomas Bachelot, Guy Jerusalem, mTOR inhibitors in advanced breast cancer: ready for prime time? Cancer Treatment Reviews. ,vol. 39, pp. 742- 752 ,(2013) , 10.1016/J.CTRV.2013.02.005
Koichi Azuma, Junji Tsurutani, Kazuko Sakai, Hiroyasu Kaneda, Yasuhito Fujisaka, Masayuki Takeda, Masahiro Watatani, Tokuzo Arao, Taroh Satoh, Isamu Okamoto, Takayasu Kurata, Kazuto Nishio, Kazuhiko Nakagawa, Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure Biochemical and Biophysical Research Communications. ,vol. 407, pp. 219- 224 ,(2011) , 10.1016/J.BBRC.2011.03.002
Simon N Stacey, Andrei Manolescu, Patrick Sulem, Steinunn Thorlacius, Sigurjon A Gudjonsson, Gudbjörn F Jonsson, Margret Jakobsdottir, Jon T Bergthorsson, Julius Gudmundsson, Katja K Aben, Luc J Strobbe, Dorine W Swinkels, K C Anton van Engelenburg, Brian E Henderson, Laurence N Kolonel, Loic Le Marchand, Esther Millastre, Raquel Andres, Berta Saez, Julio Lambea, Javier Godino, Eduardo Polo, Alejandro Tres, Simone Picelli, Johanna Rantala, Sara Margolin, Thorvaldur Jonsson, Helgi Sigurdsson, Thora Jonsdottir, Jon Hrafnkelsson, Jakob Johannsson, Thorarinn Sveinsson, Gardar Myrdal, Hlynur Niels Grimsson, Steinunn G Sveinsdottir, Kristin Alexiusdottir, Jona Saemundsdottir, Asgeir Sigurdsson, Jelena Kostic, Larus Gudmundsson, Kristleifur Kristjansson, Gisli Masson, James D Fackenthal, Clement Adebamowo, Temidayo Ogundiran, Olufunmilayo I Olopade, Christopher A Haiman, Annika Lindblom, Jose I Mayordomo, Lambertus A Kiemeney, Jeffrey R Gulcher, Thorunn Rafnar, Unnur Thorsteinsdottir, Oskar T Johannsson, Augustine Kong, Kari Stefansson, Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nature Genetics. ,vol. 40, pp. 703- 706 ,(2008) , 10.1038/NG.131